Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: A cardiovascular magnetic resonance study

Heart

Volumn 92, Issue 6, 2006, Pages 798-803

  Prasad, Sanjay K ^a   Dargie, H J ^b   Smith, G C ^a   Barlow, M M ^b   Grothues, F ^a   Groenning, B A ^b   Cleland, J G F ^c   Pennell, D J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; ENALAPRIL; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENRASENTAN; NORADRENALIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPEPSIA; ENDOCARDITIS; FATIGUE; FEMALE; FLUSHING; HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SINUSITIS; THORAX PAIN; THROMBOPHLEBITIS; VIRUS INFECTION;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARBOXYLIC ACIDS; DISEASE PROGRESSION; ENALAPRIL; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INDANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33744483519     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.049734     Document Type: Article

References (22)

1. Yanagisawa M, Kurihara H, Kimura S. A novel vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
2. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995;96:1059-65.
3. Spieker LE, Noll G, Ruschitzka FT, et al. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 2001;37:1493-505.
4. Sorensen SS, Madsen JK, Pedersen EB. Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol 1994;266:F411-8.
5. Hautala N, Tokola H, Luodonpaa M. Pressure overload increases GATA4 binding activity via endothelin-1. Circulation 2001;103:730-5.
6. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997;96:1976-82.
7. Willette RN, Anderson KM, Nelson AH, et al. Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction. J Cardiovasc Pharmacol 2001;38:606-17.
8. Bellenger NG, Francis JM, Davies CL, et al. Establishment and performance of a magnetic resonance cardiac function clinic. J Cardiovasc Magn Reson 2000;2:15-22.
9. Colucci WS, Elkayam U, Norton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
10. Abraham T. The enrasentan co-operative randomised evaluation (ENCOR) study. J Am Coll Cardiol 2001;37:401.
11. Gulati A, Barve A, Sen AP. Pharmacology of hemoglobin therapeutics. J Lab Clin Med 1999;133:112-9.
12. MacCarthy PA, Grocott-Mason R, Prendergast BD, et al. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 2000;101:142-7.
13. Coletta AP, Cleland JG. Clinical trials update: highlights of the Scientific Sessions of the XXIII Congress of the European Society of Cardiology: WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 2001;3:747-50.
14. Cowburn PJ, Cleland JGF, McDonagh TA, et al. Adverse hemodynamic effects of a selective endothelin ETB receptor antagonist in patients with chronic heart failure: reversal with a selective endothelin ETA receptor antagonist. Circulation 1998;98(suppl):I718.
15. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelin A receptor antagonist trial in heart failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:347-54.
16. Araki M, Hasegawa K, Iwai-Kanai E, et al. Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes. J Am Coll Cardiol 2000;36:1411-8.
17. Packer M. ENABLE trial: a phase III bosentan study in chronic heart failure. J Am Coll Cardiol 2002;39:171.
18. Moreau P, d'Uscio LV, Shaw S, et al. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997;96:1593-7.
19. Remme WJ. Should ACE inhibition always be first-line therapy in heart failure? Lessons from the CARMEN study. Cardiovasc Drugs Ther 2003;17:107-9.
20. Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD Investigators. Circulation 1993;88:2277-83.
21. Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with 2-D echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002;90:29-34.
22. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.